Compare CRK & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | CRSP |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.9B |
| IPO Year | 1995 | 2016 |
| Metric | CRK | CRSP |
|---|---|---|
| Price | $14.20 | $56.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 17 |
| Target Price | $22.20 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $555,231,000.00 | $289,590,000.00 |
| Revenue This Year | N/A | $807.72 |
| Revenue Next Year | $23.91 | $172.52 |
| P/E Ratio | $37.61 | ★ N/A |
| Revenue Growth | 32.11 | ★ 9169.85 |
| 52 Week Low | $12.44 | $44.12 |
| 52 Week High | $28.10 | $78.48 |
| Indicator | CRK | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 59.03 |
| Support Level | $14.16 | $50.17 |
| Resistance Level | $15.22 | $56.16 |
| Average True Range (ATR) | 0.54 | 2.74 |
| MACD | 0.24 | 0.35 |
| Stochastic Oscillator | 84.20 | 76.27 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.